PrimeGen US

We are a team of dedicated scientists, clinicians, technologists and business professionals who are passionate about saving lives. We are leading the fight against acute and chronic inflammatory diseases with our patented stemXcell platform. Today, we are preparing for FDA-authorized clinical trials that will test our stemXcell MSC treatments with enhanced immunomodulatory properties for treating chronic and acute liver diseases. Additionally, we are pursuing preclinical and clinical studies for other disease models, including NASH and ASH, and are continuing our research into numerous other inflammatory diseases. Joel Marh has over 20 years of academic and industry experience leading research in mammalian and human developmental stem cell biology, somatic cell reprogramming, and gene-editing techniques in animals and cells. Currently, Joel is overseeing both the R&D and Production efforts for PrimeGen. A highly experienced financial officer with over 50 years of experience in managing company finances, including publicly listed health companies. Chang is a graduate of National Taiwan University and holds an MBA from the University of California, Los Angeles (UCLA) Business School.